<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03976245</url>
  </required_header>
  <id_info>
    <org_study_id>RAJP0001</org_study_id>
    <nct_id>NCT03976245</nct_id>
  </id_info>
  <brief_title>Advanced Therapeutics in Rheumatoid Arthritis (RA)</brief_title>
  <official_title>Advanced Therapeutics in Rheumatoid Arthritis (RA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lawson Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Academic Medical Organization of Southwestern Ontario</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lawson Health Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the retention rates of two advanced therapies, Tumour Necrosis
      Factor (TNF) and Janus kinase inhibitor (JAK) in the treatment of adults with Rheumatoid
      Arthritis (RA) over a two year period. It will also examine the ability to embed a clinical
      trial in a clinical situation using an electronic medical record (EMR).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Conventional therapies for Rheumatoid Arthritis (RA) treatment include nonsteroidal
      anti-inflammatory drugs (NSAIDs), cyclooxygenase-2 (COX-2) selective inhibitors,
      corticosteroids and disease modifying anti-rheumatic drugs (DMARDs). These therapies are
      often partially effective.

      For those patients, where conventional therapies have failed to alleviate their symptoms,
      Tumour Necrosis Factor (TNFis) is often prescribed to treat the pain and inflammation
      associated with RA. The main problem with TNFi and other advanced therapies in RA is
      retention. At least ¼ of patients stop treatment within a year and another ⅕ to ¼ in the
      second year, mostly due to secondary loss of efficacy.

      Another advanced therapy, the Janus kinase inhibitor (JAK) has demonstrated similar efficacy
      to TNFi treatment in RA. This trial will determine if using a different class of treatment
      (small molecule, oral drug, JAK kinase inhibitor) will have a better retention than a TNFi
      (using the most commonly prescribed TNFi for RA in Canada).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 2020</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Pragmatic, open-label, randomized trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Retention Rates</measure>
    <time_frame>24 months</time_frame>
    <description>Evaluation of the proportion of patients in each arm still on the randomized treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Disease Activity</measure>
    <time_frame>24 months</time_frame>
    <description>The mean change from baseline in the Clinical Disease Activity Index in each arm of the study. The Clinical Disease Activity Index measures the number of tender or swollen joints, patient global assessment of disease activity, and provider global assessment of disease activity. Total tender joint count=0-28, total swollen joint count=0-28, patient global score=0-10, provider global score=0-10. Total range score=0-76. Higher values for all subscales, tender and swollen joints, global assessments indicate higher disease activity. Scores for subscales are combined to calculate the total score.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>etanercept</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>etanercept 50 mg subcutaneously injected per week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tofacitinib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>tofacitinib 5 mg orally daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etanercept</intervention_name>
    <description>injection</description>
    <arm_group_label>etanercept</arm_group_label>
    <other_name>enbrel</other_name>
    <other_name>Brenzys</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tofacitinib</intervention_name>
    <description>tablet</description>
    <arm_group_label>tofacitinib</arm_group_label>
    <other_name>Xeljanz</other_name>
    <other_name>Jakvinus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with RA who meet criteria for obtaining an advanced therapeutic through usual
             care

          -  active RA with 5 or more swollen joints

          -  seropositive

          -  presence of erosions

          -  failure of methotrexate and hydroxychloroquine and sulfasalazine

          -  failure of Leflunomide

             -&gt; or equal to 18 years

          -  able to provide consent

          -  able to attend usual follow up visits

        Exclusion Criteria:

          -  no contraindication to etanercept or tofacitinib

          -  active serious infection

          -  active TB

          -  multiple sclerosis

          -  current cancer

          -  lymphoma ever

          -  previous use of an advanced therapeutic (biologic or JAK kinase inhibitor)

          -  less than 18 years of age

          -  unable to provide consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janet E Pope, MD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Western Ontario, Canada</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Janet E Pope, MD MPH</last_name>
    <phone>519 646-6000</phone>
    <phone_ext>66332</phone_ext>
    <email>janet.pope@sjhc.london.on.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rheumatology Clinic, St. Joseph's Health Care</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4V2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janet E Pope</last_name>
      <phone>519-646-6332</phone>
      <email>janet.pope@sjhc.london.on.ca</email>
    </contact>
    <investigator>
      <last_name>Janet E Pope</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>June 3, 2019</study_first_submitted>
  <study_first_submitted_qc>June 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2019</study_first_posted>
  <last_update_submitted>February 24, 2020</last_update_submitted>
  <last_update_submitted_qc>February 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tumour Necrosis Factor</keyword>
  <keyword>Janus kinase inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
    <mesh_term>Tofacitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

